Stifel Financial Corp Sage Therapeutics, Inc. Transaction History
Stifel Financial Corp
- $93.2 Billion
- Q3 2024
A detailed history of Stifel Financial Corp transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 12,047 shares of SAGE stock, worth $88,545. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,047
Previous 15,449
22.02%
Holding current value
$88,545
Previous $167,000
48.5%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding SAGE
# of Institutions
195Shares Held
46.5MCall Options Held
402KPut Options Held
209K-
Vanguard Group Inc Valley Forge, PA5.76MShares$42.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.59MShares$41.1 Million0.64% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$38.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.8 Million0.54% of portfolio
-
State Street Corp Boston, MA2.93MShares$21.5 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $437M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...